ALK and non-small cell lung carcinoma: The Vysis LSI ALK break apart FISH probe kit (Abbott Molecular) was used to identify patients with ALK rearrangement positive NSCLC in the first clinical trials, and therefore the US Food and Drug Administration (FDA) approved this commercially available assay as a companion diagnostics for detection of ALK rearrangements [1].